Clinical Trial

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB(tumors \>4 cm in diameter)will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-26
Trial Details
NCT Number NCT06288373
Lead Sponsor Tongji Hospital
Collaborators: Southwest Hospital, China, Women's Hospital School Of Medicine Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Cancer Hospital of Guangxi Medical University
Conditions Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
Enrollment 440 participants
Start Date 2024-04-22
Primary Completion 2031-03-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-30